Satellos Bioscience (NASDAQ:MSLE) Downgraded by Wall Street Zen to “Strong Sell”

Satellos Bioscience (NASDAQ:MSLE) was downgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday.

A number of other brokerages have also weighed in on MSLE. HC Wainwright increased their price target on Satellos Bioscience to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Cantor Fitzgerald initiated coverage on Satellos Bioscience in a research note on Wednesday, March 11th. They set an “overweight” rating on the stock. Zacks Research raised Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. Leerink Partners initiated coverage on Satellos Bioscience in a research note on Monday, April 6th. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Weiss Ratings initiated coverage on Satellos Bioscience in a research note on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $15.50.

Satellos Bioscience Trading Up 2.5%

MSLE stock opened at $6.98 on Friday. Satellos Bioscience has a 1 year low of $4.53 and a 1 year high of $13.39. The company has a 50 day moving average of $8.63. The stock has a market cap of $145.39 million, a price-to-earnings ratio of -4.50 and a beta of 1.37.

Satellos Bioscience (NASDAQ:MSLE) last posted its earnings results on Friday, March 27th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.11). On average, analysts anticipate that Satellos Bioscience will post -2.04 EPS for the current year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.